Diagnostic test for Mammalian TB

Descriptions

The Animal and Plant Health Agency (APHA) is seeking to identify existing and potential manufacturers and/or suppliers of field-deployable diagnostic tests for mammalian tuberculosis, including those with products currently under development or those willing to collaborate with APHA to create such solutions.

Information is required (detailed in the 'Engagement' section below) on the development status of mammalian diagnostic tests that could become available for use in 2026 or 2027. This market intelligence will support the strategy for controlling mammalian tuberculosis (particularly in badgers), improve understanding of TB epidemiology in wildlife reservoirs, and assess potential transmission risks to livestock.

At this stage, APHA is gathering market intelligence only; therefore, estimated volumes and a contract value are not provided.

Engagement

Interested organisations are invited to submit the requested information (outlined below), via email, to Melanie Swain (melanie.swain@defra.gov.uk), by 30th January 2026: - Details of any suitable product(s) currently under development. - The type(s) of test being developed or already available. - The underlying technology used in the test(s). - Practical considerations for field deployment, including portability, power requirements, and methods for obtaining and recording test results. - Knowledge or training requirements for operators/end-users. - Ability and willingness to incorporate diagnostic targets into the test (e.g., antigens) as specified by APHA. - Whether antigen production capability exists alongside test production. - The nature and minimum volume of the diagnostic sample required for testing. - Time required to obtain a test result. - Operational temperature range. - Storage conditions and shelf-life. - Species for which the test is developed or intended. - Expected or demonstrated performance metrics, including sensitivity, specificity, and predictive values (positive and negative). - Any data on cross-reactivity with environmental mycobacteria, BCG vaccine (DIVA capability), or other common pathogens. - Information on validation, reproducibility, and repeatability. - Estimated date of product availability. - Evidence of use in other regions or countries. - Details of any licences or certifications held or required. - Indicative wholesale and retail pricing information, if available. This Notice is for information-gathering purposes only. It does not constitute a call for competition and does not guarantee any future procurement activity. Should a tender opportunity arise, suppliers will need to formally express their interest following the publication of a Contract Notice on Find a Tender. APHA reserves the right to follow up with suppliers on a 1:1 basis to further understand their capabilities regarding this requirement.